Supplementary Tables 1-2 and Supplementary Figures 1-6 from Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models

Abstract

Supplementary Table S1: Evaluation of M3814 (MSC2490484) in kinase assays Supplementary Table S2: In vitro activity of M3814 in combination with a single dose of gamma radiation in a panel of 93 cell lines. Supplementary Table S3: Pharmacokinetic data for M3814 Supplementary Figure S1: 3 Gy IR - M3814 combination profiling: Bliss data Supplementary Figure S2: 70 Drug - M3814 combination profiling: Bliss data Supplementary Figure S3: Concentration of M3814 in vitro, following administration of M3814 intravenously (0.2 mg/kg) or orally (0.5 mg/kg) Supplementary Figure S4: Additional 1-week IR combination efficacy data (A549, BxPC3, Capan-1, HCT-116) Supplementary Figure S5: Scheduling of M3814 relative to IR Supplementary Figure S6: Body weight curves from efficacy studies